-
Mashup Score: 34Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohort - 1 day(s) ago
Breast cancer (BC) is the second most common cancer that metastasizes to the brain. Particularly up to half of patients with human epidermal growth factor receptor 2 (HER2)-positive (HER2+) metastatic breast cancer (mBC) may develop brain metastases over the course of the disease. Nevertheless, little is known about the prevalence and the outcome of brain and leptomeningeal metastases (BLMM) in HER2-low BC. We compared the cumulative incidence of BLMM and associated outcomes among patients with HER2-low, HER2-negative (HER2−) and HER2+ mBC.
Source: www.esmoopen.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 42Antibody–drug conjugates are active in patients with HER2-positive breast cancer brain metastases: where do we go from here? - 15 day(s) ago
In this issue of ESMO Open, Hurvitz and colleagues1 report an exploratory analysis of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in the subgroup of 82 patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer and baseline brain metastases (BrMs) from the landmark DESTINY-Breast03 clinical trial. Impressively, the intracranial response rate (i-ORR) was 65.7% with T-DXd versus 34.3% with T-DM1 confirming antibody–drug conjugates (ADCs) as a promising strategy in treating breast cancer BrMs.
Source: www.esmoopen.comCategories: General Medicine News, Onc News and JournalsTweet-
Antibody–drug conjugates are active in patients with HER2+ breast cancer brain metastases: where do we go from here? Read the editorial on the brain mets analysis from DB03 by Sarah Sammons (@drsarahsam) and Nancy Lin (@nlinmd) from @DFCI_BreastOnc. https://t.co/QkQ1XNVmZU https://t.co/k3TanjNSiH https://t.co/TuycSzyo5Q
-
-
Mashup Score: 71
DESTINY-Breast03 is a randomized, multicenter, open-label, phase III study of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC) previously treated with trastuzumab and a taxane. A statistically significant improvement in progression-free survival (PFS) versus T-DM1 was reported in the primary analysis. Here, we report exploratory efficacy data in patients with and without brain metastases (BMs) at baseline.
Source: www.esmoopen.comCategories: General Medicine News, Onc News and JournalsTweet-
Out in @ESMO_Open the intracranial activity of T-DXd vs T-DM1 in the DESTINY-Breast03 phase 3 trial. Among patients with active brain mets, IC-ORR was 65.7% with T-DXd vs 34.3% with T-DM1. Accompanied by a podcast 🎙️ & an editorial by @drsarahsam @nlinmd. https://t.co/O8gytcXcq3 https://t.co/qTkTxbhGua
-
-
Mashup Score: 28
Fifteen to thirty percent of all patients with metastatic breast cancer (MBC) develop brain metastases (BCBMs). Recently, the antibody–drug conjugates (ADCs) sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd) have shown to be highly effective in the treatment of MBC. However, there are only limited data whether these macromolecules are also effective in patients with BCBMs. We therefore aimed to examine the efficacy of SG and T-DXd in patients with stable and active BCBMs in a multicenter real-world analysis.
Source: www.esmoopen.comCategories: General Medicine News, Onc News and JournalsTweet-
What is the real-world intracranial activity of T-DXd & SG for breast cancer brain mets (BCBM)? In this 🇩🇪 cohort of 26 patients with BCBM, icDCR was 42% in patients receiving SG for triple negative BCBM and 88% if receiving T-DXd for HER2+/HER2-low BCBM. https://t.co/GPZa0sRCzA https://t.co/aak6AY9N0L
-
-
Mashup Score: 5Susana Banerjee | ESMO Board Member - 22 day(s) ago
Susana Banerjee is on the Advisory Board for Nature Reviews Clinical Oncology journal and Editorial Boards of Cancer Treatment Reviews and ESMO Open
Source: www.esmo.orgCategories: General Medicine News, Onc News and JournalsTweet-
Our Editor Spotlight this week is Susana Banerjee, MBSS PhD (@BanerjeeSusana), @ESMO_Open Editor for Gynecologic oncology. Dr. Banerjee’s work focuses on novel systemic treatments and translational research for ovarian, endometrial and cervical cancers. https://t.co/mycAk7xKcQ https://t.co/OHkFZIaE3H
-
-
Mashup Score: 26
The majority of patients who are diagnosed with cutaneous melanoma are candidates for surgical resection and thus curable from their disease. However, the risk for a recurrence is high for many patients, including those with lymph node-negative melanoma, thus necessitating additional therapies beyond surgery. With the advent of anti-programmed cell death protein 1 (PD-1)-based immunotherapies, which are vastly more effective compared to previous standard-of-care treatments in the advanced setting, the landscape of adjuvant therapy has fundamentally changed in recent years.
Source: www.esmoopen.comCategories: General Medicine News, Onc News and JournalsTweet-
Adjuvant immunotherapy for melanoma patients: progress and opportunities. Don’t miss the latest Open Access review by Drs. Sussman and Ott, recapitulating recent advancements and future perspectives in the curative treatment of melanoma with immunotherapy. https://t.co/DxXIOX9hZ1 https://t.co/Y7oZhAVKOf
-
-
Mashup Score: 36Subtyping of triple-negative breast cancers: its prognostication and implications in diagnosis of breast origin - 26 day(s) ago
Triple-negative breast cancer (TNBC) subtyping by gene profiling has provided valuable clinical information. Here, we aimed to evaluate the relevance of TNBC subtyping using immunohistochemistry (IHC), which could be a more clinically practical approach, for prognostication and applications in patient management.
Source: www.esmoopen.comCategories: General Medicine News, Onc News and JournalsTweet-
TNBC is commonly treated as a unitary entity, although distinct subtypes have been recognized within this definition. Here, Dr. Hu et al. used IHC-based subtyping among 123 patients with TNBC, demonstrating distinct features and outcomes across subtypes. https://t.co/lIeGdCVpdX https://t.co/h4dkIh9qZP
-
-
Mashup Score: 42
Targeted therapy (TT) with encorafenib and cetuximab is the current standard for patients with BRAFV600E-mutated metastatic colorectal cancer (mCRC) who received one or more prior systemic treatments. However, the median progression-free survival (mPFS) is ∼4 months, and little is known about the possibility of administering subsequent therapies, their efficacy, and clinicopathological determinants of outcome.
Source: www.esmoopen.comCategories: General Medicine News, Onc News and JournalsTweet-
What are the treatment patterns and outcomes for patients with BRAF-mutant mCRC after progression to encorafenib/cetiximab? In this article, Dr. Germani et al. report data from a large 🇮🇹 cohort, suggesting improved outcomes when TT is administered early. https://t.co/hsEW5hfRn2 https://t.co/OTxrV66e69
-
-
Mashup Score: 14John Haanen | ESMO - 30 day(s) ago
ohn Haanen finished his MD at Leiden University cum laude in 1988.
Source: www.esmo.orgCategories: General Medicine News, Onc News and JournalsTweet-
Our Editor Spotlight this week is John B. Haanen, MD PhD (@HaanenJohn), @ESMO_Open Editor for Immunotherapy. Dr. Haanen’s work focuses on the development of innovative immunotherapies, including antibodies, vaccines, gene therapies and cellular therapies. https://t.co/AMahj6o9YN https://t.co/s9RD1bl8DU
-
-
Mashup Score: 20Paolo A. Ascierto | ESMO - 1 month(s) ago
Paolo A. Ascierto obtained his medical degree from the University of Naples Federico II, Italy
Source: www.esmo.orgCategories: General Medicine News, Onc News and JournalsTweet
Does HER2-low expression impact the incidence of brain metastases from breast cancer? In a large analysis from the ESME database, Dr. Epaillard et al. demonstrate similar incidence and outcomes of brain mets for HER2-low vs HER2-0 metastatic breast cancer. https://t.co/TkPr9yqiB8 https://t.co/v3axElp0zr